Facebook Linkedin Soundcloud Twitter Vimeo Xing
Home Tags BYON3521

Tag: BYON3521

A Preclinical Profile of the Potential of BYON3521

ADC Review | Editorial Team
A recent article, published in Molecular Cancer Therapeutics, an American Association for Cancer Research (AACR) journal, suggests that BYON3521, a next-generation antibody-drug conjugate being developed by clinical-stage Dutch...

First Patient Dosed in Phase 1 Study of Next Generation Antibody-Drug...

ADC Review | Editorial Team
BYON3521, a new ADC targeting c-Met, has entered phase 1 (BYON3521.001/NCT05323045) clinical development when, earlier this week, a first patients had been dosed with the investigational drug being developed...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X